Paradigm Spine will attend at the North American Spine Society's Annual Meeting in San Francisco from Nov. 12 to 15.
The company focuses on non-fusion spinal implant technology. Its proprietary coflex Interlaminar Technology is indicated for use in one- or two-level lumbar stenosis from L1-L5 in adult patients.
In July, the company published two separate independent prospective clinical studies that examined the short-and long-term durability of coflex interlaminar stabilization.
More articles on devices:
Alphatec Spine 3Q revenue up 2%: 10 key concepts
NuVasive's 3Q revenue up 12.3%: 10 things to know
Zimmer Biomet names new leaders